Eurofins Scientific SE (EPA:ERF)
63.18
-0.48 (-0.75%)
At close: Mar 11, 2026
Eurofins Scientific SE Employees
Eurofins Scientific SE had 65,694 employees as of December 31, 2025. The number of employees increased by 2,998 or 4.78% compared to the previous year.
Employees
65,694
Change (1Y)
2,998
Growth (1Y)
4.78%
Revenue / Employee
€111,062
Profits / Employee
€6,334
Market Cap
11.13B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 65,694 | 2,998 | 4.78% |
| Dec 31, 2024 | 62,696 | 898 | 1.45% |
| Dec 31, 2023 | 61,798 | 419 | 0.68% |
| Dec 31, 2022 | 61,379 | 3,387 | 5.84% |
| Dec 31, 2021 | 57,992 | 6,476 | 12.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 200,000 |
| emeis Société anonyme | 83,500 |
| Sanofi | 74,846 |
| Clariane SE | 61,798 |
| Ramsay Générale de Santé | 40,494 |
| bioMérieux | 14,754 |
| Sartorius Stedim Biotech | 10,265 |
| Virbac | 6,365 |
Eurofins Scientific SE News
- 23 days ago - Eurofins Scientific : Director/PDMR Shareholding - Business Wire
- 4 weeks ago - Eurofins Scientific: Director/PDMR Shareholding - Business Wire
- 4 weeks ago - Eurofins Scientific SE: Weekly Report on Share Repurchases from 02nd February to 06th February 2026 • news - Onvista
- 5 weeks ago - Eurofins Scientific SE (ERFSF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Eurofins Scientific SE: Director/PDMR Shareholding - Business Wire
- 3 months ago - Eurofins Scientific SE: Director/PDMR Shareholding - Business Wire
- 4 months ago - Eurofins Scientific: Growth, Repurchase Program, And Low Debt Make An Excellent Combination - Seeking Alpha
- 5 months ago - Eurofins Scientific SE (ERFSF) Q3 2025 Sales Call Transcript - Seeking Alpha